Navigation Links
Sorafenib Shows Promise for Heart-Lung Disease
Date:5/20/2008

Cancer drug interferes with abnormal cell growth seen in pulmonary hypertension

TUESDAY, May 20 (HealthDay News) -- The cancer drug sorafenib (Nexavar) shows promise as a treatment for pulmonary hypertension, according to a University of Chicago Medical Center study.

During the study, nine patients took the drug for 16 weeks at doses lower than those given to cancer patients. The patients also continued to take their standard medications.

Eight of the patients increased their ability to exercise, six showed significant improvements in their right ventricular ejection fraction (the ability of the heart to pump blood to the lungs), and four had a significant decrease in pulmonary artery pressures.

The most common side effects were diarrhea and hair loss.

The findings were expected to be presented May 20 at the American Thoracic Society annual meeting, in Toronto.

"This is not a disease where we are used to seeing people who have been stable on the strongest medications we have suddenly get better. We have drugs that may slow progression of the disease, but nothing that can stop or reverse the process," study author Dr. Mardi Gomberg-Maitland, an assistant professor of medicine, said in a prepared statement.

"To see these improvements in such a short time is quite promising. Although evaluation of this drug is at a very early stage, and this study focused on safety and tolerability, we are genuinely excited about the results," Gomberg-Maitland said.

Sorafenib was originally developed at the University of Chicago as a treatment for kidney cancer. Both cancer and pulmonary hypertension involve abnormal cell growth. In pulmonary hypertension, the abnormal cell growth occurs in blood vessels that lead to the lungs, causing the vessels to thicken and narrow. This means the heart has to work harder to pump blood to the lungs. This extra workload damages the heart.

Sorafenib appears to interfere with the abnormal cell growth seen in pulmonary hypertension.

Researchers are now organizing a multi-center trial of the drug in patients with pulmonary hypertension.

More information

The U.S. National Heart, Lung, and Blood Institute has more about pulmonary hypertension.



-- Robert Preidt



SOURCE: University of Chicago Medical Center, news release, May 19, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Sorafenib Slows Growth of Some Leukemias
3. With age comes a sense of peace and calm, population research center study shows
4. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
5. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
6. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
7. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
8. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
9. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
10. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
11. Research shows HPV testing offers women protection for twice as long as smear testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced a ... By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization part ... of a needle stick and more importantly, helps our staff members locate a vein ...
(Date:8/16/2017)... YORK, NY (PRWEB) , ... August 16, 2017 , ... ... for better treatments and ultimately, a cure. , The grants are awarded through ... comprised of scientists with a wide array of backgrounds and expertise in all areas ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, ... Strawn of God's love, and all the many ways God shows love to ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... to patients suffering from chronic pelvic pain. In addition to oncology services, ... pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during menstruation), uterine fibroids, and ...
(Date:8/16/2017)... West Orange, NJ (PRWEB) , ... August 16, 2017 , ... With low back pain ... not even know what causes its kissing cousin – upper back pain. But this equally ... bevy of treatment options, according to Kaixuan Liu, MD, PhD , founder and president ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/24/2017)... , July 24, 2017 IBM (NYSE: ... Gartner Magic Quadrant for Solid-State Arrays (SSA) for the fourth ... According to Gartner, "Vendors in the Leaders quadrant ... Completeness of Vision. A vendor in the Leaders quadrant has ... to drive the acceptance of new technologies. These vendors demonstrate ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
Breaking Medicine Technology: